November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
August 2022 in “Dermatology Online Journal” Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.
18 citations
,
December 2017 in “Medicine” Adding celecoxib to chemotherapy improves survival and quality of life for gastric cancer patients with positive COX-2.
October 2023 in “Regular and Young Investigator Award Abstracts” Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.
January 2024 in “Pharmacoepidemiology” Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
January 2025 in “International Journal of Pharmaceutics” The treatment showed significant hair regrowth in alopecia areata patients without side effects.
September 2023 in “Journal of the American Academy of Dermatology” Psoriasis and gout are linked, with each increasing the risk of the other.
August 2018 in “Journal of The American Academy of Dermatology” Different treatments for skin conditions were found to be effective and generally safe, with biologics recommended as the first choice for generalized pustular psoriasis.
5 citations
,
May 2023 in “Clinical Rheumatology” Tofacitinib helped regrow hair in a lupus patient with alopecia.
16 citations
,
July 2017 in “Rheumatology and Therapy” Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
42 citations
,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
68 citations
,
September 2003 in “British Journal of Dermatology” Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
136 citations
,
April 2013 in “Clinical Cancer Research” The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
29 citations
,
December 2019 in “Expert review of clinical pharmacology” JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
1 citations
,
April 2019 in “Reumatología Clínica (English Edition)” Leflunomide and methotrexate are similarly effective for rheumatoid arthritis but have different side effects.
February 2026 in “Clinical Drug Investigation” Baricitinib significantly improves nail and hair symptoms in severe alopecia areata.
10 citations
,
January 2018 in “International Journal of Trichology” Mesalazine may help treat extensive alopecia areata effectively.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
May 2024 in “Frontiers in Medicine” Targeted immunological therapies offer safer and more effective treatments for skin conditions like eczema and psoriasis.
1 citations
,
January 2008 in “SKINmed Dermatology for the Clinician” Treatment with prednisolone and dapsone stopped new blisters and partially healed previous ones.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
15 citations
,
January 2022 in “Immune Network/Immune network” New targeted immunotherapies are improving treatment for inflammatory skin diseases.
July 2003 in “Journal of Cutaneous Medicine and Surgery” Some medications can improve skin conditions, while lifestyle factors like smoking and drinking may worsen them; treatments like monoclonal antibodies and imiquimod cream show promise for certain skin diseases.
49 citations
,
August 2018 in “International Journal of Dermatology” Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
February 2026 in “Frontiers in Immunology” Tralokinumab for atopic dermatitis may cause eye issues and skin reactions, needing careful monitoring.
12 citations
,
June 2016 in “Clinical and Molecular Hepatology” Mycophenolate mofetil can effectively treat autoimmune hepatitis when standard drugs fail.
3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
April 2024 in “Clinical and experimental dermatology” Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.